Absolutely, see my post above. I believe NEU are now preparing for acquisition and conducting a PW P2 trial does not fit within this timeline (and would provide questionable additional value given 2591 has now already been proven in 2 synaptopathies and hopefully 3 soon). Any BP acquirer will have the optionality of pursuing PW as well as the "undisclosed indications" NEU is providing proof-of-principle evidence for.
Ann: Phase 2 trial shows significant improvements in Pitt Hopkins, page-143
-
- There are more pages in this discussion • 18 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$15.57 |
Change
-0.040(0.26%) |
Mkt cap ! $1.990B | |||
| Open | High | Low | Value | Volume |
| $15.83 | $15.87 | $15.20 | $8.124M | 524.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 64 | $15.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $15.58 | 597 | 1 |
View Market Depth
| Last trade - 16.10pm 16/08/2024 (20 minute delay) ? |
| NEU (ASX) Chart |